Before anti-PD-1 approval in France, the comparative PRODIGE58-UCGI35-REGIRI study was designed to detect the superiority of REGO plus IRI versus IRI alone on OS as 2L treatment in mGA patients, using a 1 : 1 randomisation design and stratification by prior use of PD-1/PD-L1 inhibitors and location of tumour. The gene discussed is PDCD1; the disease is neoplasm.